GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A3735 PreladenantTarget: Adenosine A2A ReceptorsSummary: Adenosine A2A receptor antagonist
-
A3885 TozadenantTarget: Adenosine A2A ReceptorsSummary: Adenosine 2a receptor antagonist,novel and selective
-
A8454 Istradefylline (KW-6002)Target: Adenosine A2A ReceptorsSummary: Selective A2A receptor antagonist
-
B2214 ValsartanTarget: Angiotensin AT1 ReceptorsSummary: Angiotensin II AT1 receptor antagonist
-
B5904 Regadenoson1 CitationTarget: Adenosine A2A ReceptorsSummary: Highly selective and low affinity A2A adenosine agonist
-
B5612 BAY 60-6583Target: Adenosine A2B ReceptorsSummary: Potent A2B receptor agonist
-
B6995 SCH 58261Target: Adenosine A2A ReceptorsSummary: A2A adenosine receptor competitive antagonist